DEERFIELD, Ill., April 16, 2014 - Baxter International Inc. (NYSE:BAX) marks World Hemophilia Day, observed annually by the World Federation of Hemophilia and the global hemophilia community to raise awareness of the disease and other bleeding disorders. This year, the observance encourages the community to, "Speak out. Create change."
As part of Baxter's continued support of the hemophilia community, the company is issuing a position paper on hemophilia care outlining its vision for the future of hemophilia, including reducing and preventing bleeding episodes. As stated in the paper, Baxter encourages increased collaboration to improve the quality and access to comprehensive care for hemophilia patients worldwide. This position paper can be found here.
"As a long-standing, established leader in the global hemophilia community, Baxter has been an ardent supporter of World Hemophilia Day as part of ongoing efforts to improve standards of care and reduce the burden on people with this chronic disease," said Brian Goff, leader of Baxter's global hemophilia organization. "Together with our partners, we are striving to raise the bar for quality care and pursue our vision of a bleed-free world."
Baxter's history of scientific leadership and long-term commitment to research and development activities aim to identify treatments for individual patient needs through prevention of bleeds and tailored dosing schedules. In addition to advancing innovative therapies and new indications, the company continues to be an active global supporter of the hemophilia communities, with continued supply of product donations and initiatives to increase global access to care.
World Hemophilia Day occurs each year on April 17. Since its creation in 1989, in honor of the World Federation of Hemophilia's founder, Frank Schnabel, World Hemophilia Day has served as an opportunity to increase awareness of hemophilia and other bleeding disorders and their impact on the global community.
About Baxter in Hemophilia
Baxter has more than 60 years' experience in hemophilia and has introduced a number of therapeutic firsts for hemophilia patients. Baxter has the broadest portfolio of hemophilia treatments in the industry and is able to meet individual therapy choices, providing a range of options at each treatment stage. The company's work focuses on optimizing hemophilia care and improving the lives of people worldwide living with bleeding disorders.
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.